ClinicalTrials.gov
public full text
Public Domain
Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
The aim of the study is to evaluate, after radiological progression, efficacy in patients treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best supportive care. Primary efficacy objective is progression free survival from randomization.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma#1339751
- Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)#865996
- Sorafenib Chemoembolization Evaluation Controlled Trial#1410905
- Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC#906552
- Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)#1183758
Record · ID 1484654
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive